Cigna Corp (CI · NYSE)

CI · MARKET VIEW

Market view · as of Sep 28, 2026

Revenue (TTM)
$282.38B
+6.7% YoY
Gross margin
9.1%
EPS (latest q)
$7.78
vs $7.58 est · beat
52-wk position
50.7%
-10.6% vs 52w high · -1.5% 1mo

Price (last ~year)

Cigna beat estimates in all four of its most recent quarters, including Q2 2026 EPS of $7.78 versus $7.58 expected, while revenue grew 6.7% year over year to $71.67B in the June quarter. The stock trades at a P/E of 11.25 with a PEG of 0.751 and an analyst target of $341.83, though shares sit 10.6% below their 52-week high with a 1.6% 20-day volatility. Operating cash flow turned negative at -$421.0M in the June quarter against $297.0M in capex, leaving free cash flow at -$718.0M, while leverage stands at 2.5x debt/EBITDA on $31.88B of total debt. The company announced a collaboration with OpenAI to integrate AI tools into clinical workflows for complex conditions, starting with cancer care.

Valuation

Market cap
$71.88B
P/E
11.25
PEG
0.751
P/B
1.711
P/S
0.255
EV/EBITDA
7.64
Beta
0.317
Analyst target
$341.83

Quality & returns

Gross margin
9.1%
Operating margin
4.0%
Profit margin
2.3%
ROE
16.8%
ROA
4.5%

Price movement

Last
$272.01
1-month
-1.5%
3-month
-1.3%
RSI (14)
41
vs SMA200
-1.8%
52-wk position
50.7% -10.6% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-06-30$71.67B$2.68B$1.66B$2.61B
2026-03-31$68.49B$2.36B$1.65B$3.28B
2025-12-31$72.47B$2.15B$1.23B$2.54B
2025-09-30$69.75B$2.58B$1.87B$3.34B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots